公开(公告)号：US11091441B2

公开(公告)日：2021-08-17

申请号：US17069386

申请日：2020-10-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert Bichler ,  Jean-Jacques Alexandre Cadieux ,  Matthew David Tandy ,  Gregory N. Beatch

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US20210169839A1

公开(公告)日：2021-06-10

申请号：US17109937

申请日：2020-12-02

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Jacques Alexandre Cadieux ,  Matthew David Tandy

IPC: A61K31/27 ,  A61K9/00 ,  A61K47/38 ,  A61K47/36 ,  A61K47/10 ,  A61K47/32

Abstract: Disclosed herein are immediate-release oral pharmaceutical formulations comprising a therapeutically effective amount of ezogabine and one or more pharmaceutically acceptable excipients for use in treating epilepsy and/or epileptic seizure disorders in a mammal, preferably a human, more preferably a child. Also disclosed are methods of using and making the immediate-release oral pharmaceutical formulations.

公开(公告)号：US20240279182A1

公开(公告)日：2024-08-22

申请号：US18540582

申请日：2023-12-14

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert Bichler ,  Jean-Jacques Alexandre Cadieux ,  Matthew David Tandy ,  Gregory N. Beatch

IPC: C07D217/04

CPC classification number: C07D217/04 ,  C07B2200/13

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US20230404913A1

公开(公告)日：2023-12-21

申请号：US18248661

申请日：2021-04-09

Applicant: Xenon Pharmaceuticals, Inc.

Inventor： Jean-Jacques Alexandre Cadieux ,  Matthew David Tandy

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/10 ,  A61K9/28 ,  A61K31/635 ,  A23L33/00 ,  A23L33/125

CPC classification number: A61K9/0053 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1617 ,  A61K9/2054 ,  A61K9/2013 ,  A61K9/10 ,  A61K9/2866 ,  A61K31/635 ,  A23L33/40 ,  A23L33/125

Abstract: Provided herein are certain pharmaceutical compositions comprising (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzene-sulfonamide (Compound A), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions can be present in form of an immediate release tablet, a granular formulation, a stable suspension oral dosage form or a multi-particulate sprinkle dosage form. Methods for the treatment of a disease or a condition associated with Naj4.6 activity, such as epilepsy, are described.